Zepp Health To Host Wearables Data in Healthcare State-of-the-Union Event with Industry Thought Leaders on January 5, 2022
CUPERTINO, Calif., Jan. 4, 2022 /PRNewswire/ -- Zepp Health Corp. (NYSE: ZEPP) today announced that it will host an event to share thoughts among industry leaders on the current state and path forward in the use of data in healthcare from smart wearable devices. Speakers will include: Zepp Health Chairman & CEO Wayne Huang providing industry perspective International...
Molecular Stethoscope, Inc. establishes new Corporate Headquarters and Research & Development Laboratories in South San Francisco and appoints Gajus Worthington to its Board of Directors
SOUTH SAN FRANCISCO, Calif., Jan. 4, 2022 /PRNewswire/ -- Molecular Stethoscope, a leading Precision Medicine biotechnology company pioneering the next-generation cf-mRNA Liquid Biopsy, announced today that it has joined Verily Life Sciences ("Verily") partnered laboratory ecosystem in South San Francisco and appointed Gajus Worthington to its Board of Directors. The Company is...
Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Jan. 4, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, its next generation anti-CTLA-4 fully human heavy-chain only antibody (HCAb), HBM4003, has completed the first dosing of first patient in two phase I trials for the treatment of advanced hepatocellular carcinoma (HCC)...
Alamar Biosciences partners with Abcam to drive understanding of the human proteome
FREMONT, Calif. and CAMBRIDGE, England, Jan. 4, 2022 /PRNewswire/ -- Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences research tools, today announced a strategic partnership to further understanding of...
Breakthrough Discoveries on Novel Features of Omicron Variant and An Anti-Omicron Antibody JMB2002
SHANGHAI, Jan. 4, 2022 /PRNewswire/ -- Joint research results from Biologics of Jemincare and Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences (CAS) confirmed that JMB2002, an anti-SARS-CoV-2 neutralizing antibody (NAb) discovered by Biologics of Jemincare is still effective against Omicron variant of SARS-CoV-2. A team of scientists led by Dr. Su-Jun Deng from biologics of Jemincare...
AKESO’S CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) COMBINED WITH CONCURRENT CHEMORADIOTHERAPY OBTAINED APPROVAL TO INITIATE A PHASE III CLINICAL TRIAL FOR THE TREATMENT OF LOCALLY ADVANCED CERVICAL CANCER
HONG KONG, Jan. 4, 2022 /PRNewswire/ -- Today, Akeso (09926.HK) announces that Cadonilimab (PD-1/ CTLA-4 bi-specific antibody), the first-inclass novel immuno-oncology drug independently developed by the Company, combined with concurrent chemoradiotherapy obtained approval from the Center for Drug Evaluation ('CDE') of the National Medical Products Administration of the People's Republic of China (''China'') to initiate a phase III...
TCI’s Golden Formula Has Won the Best Plant-Based Functional Product in the World Plant-Based Awards 2021
TAIPEI, Jan. 4, 2022 /PRNewswire/ -- In recent years, there has been a global trend of plant-based health care, which is known as vegetarian food in Taiwan. In the World Plant-Based Awards, jointly organized by FoodBev Media and Plant Based World Expo & Conference, TCI's Golden Formula won the best plant-based functional product of the year and is expected to win...
Gannex Announces Completion of the U.S. Phase I Trial of ASC43F, an In-House Developed First-in-Class Dual Targeting Fixed-dose Combination Tablet for NASH
ASC43F was safe and well tolerated in healthy subjects with no clinically significant study drug related adverse events Pharmacokinetic parameters of ASC41 and ASC42 from ASC43F are similar to those of ASC41 and ASC42 monotherapy Phase I trial completed two months after the U.S. IND approval, demonstrating execution excellence SHANGHAI, Jan. 4, 2022 /PRNewswire/...
Asieris Announces the World’s First Patient Dose Administered in Combination of Asieris’APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients
SHANGHAI, Jan. 4, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris), a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors, today announced that the world's first patient dose has been administered in U.S. for its oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients with muscle invasive bladder cancer (MIBC). The investigational new drug...
Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
SHANGHAI, Jan. 4, 2022 /PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in Asia, announced today that Taiwan Food and Drug Administration (TFDA) has accepted the submission of a New Drug Application (NDA) for sacituzumab govitecan (SG) in adult patients with unresectable locally advanced or metastatic...
